Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-07-11
2006-07-11
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S133100, C424S155100, C424S156100, C530S387300
Reexamination Certificate
active
07074405
ABSTRACT:
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
REFERENCES:
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 5274076 (1993-12-01), Barbet et al.
patent: 5502037 (1996-03-01), Kondratyev
patent: 5503987 (1996-04-01), Wagner et al.
patent: 5534254 (1996-07-01), Huston et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5683694 (1997-11-01), Bagshawe et al.
patent: 5851527 (1998-12-01), Hansen
patent: 6096289 (2000-08-01), Goldenberg
patent: 6187284 (2001-02-01), Griffiths
patent: 0263046 (1988-04-01), None
patent: 0419387 (1991-03-01), None
patent: 0511011 (1992-10-01), None
patent: 0623675 (1994-11-01), None
patent: WO 9604313 (1996-02-01), None
patent: WO 99/66951 (1999-12-01), None
B.T. McGuinness et al., “Phage diabody repertoires for selection of large numbers of bispecific antibody fragments,”Nature Biotechnology, 14:1149-1154 (1996).
M. Alt et al., “Novel tetravalent and bispec8ific IgG-like antibody molecules combining single chain diabodies with the immunoglobulin gamma-1 or CH3 region,”FEBS LETT, 454:90-94 (1999).
T.B. Olafsen et al., “IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic Cells,”Immunotechnology, 4(2):141-153 (1998).
S.M. Kipriyanov et al., “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics,”J. Mol. Biol.,293(1):41-56 (1999).
G. Hawkins, et al., “Deliver of Radionuclides to Pretargeted Monoclonal, Antibodies Using Dihydrofolate Reductase and Methotrexagte in an Affinity System,”Cancer Research, vol. 53, pp 2368-2373, May 1993.
David A. Goodwin, et al., “Pre-Targeted Immunoscintigraphy of Murine Tumors with Indium-111-Labeled Bifunctional Haptens,”J. Nucl, Med.,vol. 29, pp 226-234, 1998.
Dwight R. Stickney, et al., “Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma,”Cancer Research, vol. 51, pp 6650-6655, Dec. 15, 1971.
Emmanuel Gautherot, et al., “Therapy for Colon Carcinoma Xenografts with Bispecific Antobody-Targeted, Iodine-131-Labeled Bivalent Hapten,”Cancer Supplement, vol. 80, pp 2618-2623, 1997.
J. Barbet, et al., “Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA X Anti-DTPA-Indium,”The Journal of Nuclear Medicine, vol. 39, No. 7, Jul. 1998.
Marion H.G.C. Kranenborg, et al., “Development and Characterization of Anti-Renal Cell Carcinoma x Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma,”Cancer Research Supplement, vol. 55, pp 5864s-5867s, Dec. 1, 1995.
S.R. Cherry, et al., MICROPET 1: Performance Evaluation of a Very High Resolution Pet ScannerProceedings of the 44thAnnual Meeting Scientific Papers, vol. 38, No. 5, May 1997 Supplement.
Jochen Schuhmacher, et al., “Multistep Tumor Targeting in Nude Mice Using Bispecific Antibodies and a Gallium Chelate Suitable for Immunoscintigraphy with Positron Emission Tomography,”Cancer Research, vol. 55, pp 115-123, Jan. 1, 1995.
Robert M. Sharkey, et al., “Development of Streptavidin—Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method For Radioimmunotherapy of Colorectal Cancer. Studies in A Colon Cancer Xenograft Model,”Bioconjugate Chemical, vol. 8, No. 4, 1997.
H. Karacay et al., “Studies on a humanized anti-CEA x murine anti-(In- DTPA) bispecific antibody construct for radioimmunotherapy of CEA-positive tumors,”Proceedings of the American Association for Cancer Research Annual Meeting, vol. 40, p 644 (Mar. 1999).
H. Karacay et al., “Pretargeting studies with a humanized anti-CEA X murine anti-(In- DTPA) bispecific antibody construct and Tc-99m/Re-188 labeled peptide,”Journal of Nuclear Medicine, vol. 40, No. 5 Suppl., p 225 (May 1999).
E. Gautherot et al., “Delivery of therapeutic does of radioiodine using bispecific antibody-targeted bivalent haptens,”Journal of Nuclear Medicine, vol. 39 (11), pp 1937-43 (Nov. 1998).
F.K. Bodere et al., “Phase I/II total of two-step radioimmunotherapy in medullary thyroid cancer (MTC) using bispecific anti-CEA/anti- DTPA-in antibody and iodine-131-labeled bivalent hapten,”Journal of Nuclear Medicine, vol. 39, No. 5 Suppl., p 246 (May 1998).
M. Bardies et al., “Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer,”Journal of Nuclear Medicine, vol. 37, pp 1853-1859 (Nov. 1996).
Kraeber-Bodere F. et al., “Bispeciifc antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft,”Journal of Nuclear Medicine, vol. 40 (1), pp 198-204 (Jan. 1999).
M. Hosono et al., “Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.”Journal of Nuclear Medicine, vol. 39 (9), pp 1608-13 (Sep. 1998).
M.H. Kranenborg et al., “Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies,”International Journal of Cancer, vol. 75 (1), pp 74-80 (Jan. 5, 1998).
E. Gautherot et al., “Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten,”Cancer, vol. 80, No. Suppl. 12, pp 2618-2623 (Dec. 15, 1997).
K. Bosslet et al., “Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy,”British Journal of Cancer, vol. 63/5, pp 681-686 (1991).
C. Manetti et al., “Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells,”Int. J. Cancer, vol. 63(2), pp 250-256 (1995).
J. Barbet et al., “Radioimmunotherapy of LS174T colon carcinoma in nude mice using an iodine-131-labeled bivalent hapten combined with an anti-CEAX anti-indium- DTPA bispecific antibody,”Tumor Biology, vol. 18, No. Suppl. 2, p 31 (Sep. 1997).
Griffiths Gary L.
Hansen Hans J.
Leung Shui-on
McBride William J.
Qu Zhengxing
Heller Ehrman LLP
Immunomedics Inc.
Saunders David
LandOfFree
Use of bi-specific antibodies for pre-targeting diagnosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of bi-specific antibodies for pre-targeting diagnosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of bi-specific antibodies for pre-targeting diagnosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3602170